Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free PMN Stock Alerts

Promis Neurosciences (PMN) Competitors

Promis Neurosciences logo
$11.06 -0.01 (-0.09%)
Closing price 04:00 PM Eastern
Extended Trading
$11.28 +0.23 (+2.03%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

PMN vs. COEP, FRMM, GOSS, EXOZ, and BTMD

Should you be buying Promis Neurosciences stock or one of its competitors? The main competitors of Promis Neurosciences include Coeptis Therapeutics (COEP), Forum Markets (FRMM), Gossamer Bio (GOSS), eXoZymes (EXOZ), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

How does Promis Neurosciences compare to Coeptis Therapeutics?

Promis Neurosciences (NASDAQ:PMN) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Coeptis Therapeutics had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 2 mentions for Promis Neurosciences. Coeptis Therapeutics' average media sentiment score of 0.49 beat Promis Neurosciences' score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Promis Neurosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Coeptis Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Promis Neurosciences has a beta of -0.2, suggesting that its share price is 120% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500.

Promis Neurosciences currently has a consensus target price of $42.67, indicating a potential upside of 285.77%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Promis Neurosciences is more favorable than Coeptis Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Coeptis Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Promis Neurosciences has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -803.96%. Coeptis Therapeutics' return on equity of -110.89% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Promis NeurosciencesN/A -933.63% -295.33%
Coeptis Therapeutics -803.96%-110.89%-78.30%

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Coeptis Therapeutics has higher revenue and earnings than Promis Neurosciences. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Promis NeurosciencesN/AN/A-$39.72M-$19.00N/A
Coeptis Therapeutics$1.36M63.21-$11.92M-$2.98N/A

Summary

Coeptis Therapeutics beats Promis Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Promis Neurosciences compare to Forum Markets?

Forum Markets (NASDAQ:FRMM) and Promis Neurosciences (NASDAQ:PMN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Forum Markets and Forum Markets both had 2 articles in the media. Forum Markets' average media sentiment score of 0.00 equaled Promis Neurosciences'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Forum Markets
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Promis Neurosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Forum Markets has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.2, indicating that its stock price is 120% less volatile than the S&P 500.

Forum Markets presently has a consensus target price of $5.00, indicating a potential upside of 1.83%. Promis Neurosciences has a consensus target price of $42.67, indicating a potential upside of 285.77%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Forum Markets.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forum Markets
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Forum Markets' return on equity of -254.74% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Forum MarketsN/A -254.74% -132.82%
Promis Neurosciences N/A -933.63%-295.33%

4.1% of Forum Markets shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 15.1% of Forum Markets shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Promis Neurosciences has lower revenue, but higher earnings than Forum Markets. Promis Neurosciences is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forum Markets$6.55M15.23-$450.52M-$39.19N/A
Promis NeurosciencesN/AN/A-$39.72M-$19.00N/A

Summary

Forum Markets and Promis Neurosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Promis Neurosciences compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Promis Neurosciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -351.49%. Gossamer Bio's return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Gossamer Bio-351.49% N/A -75.50%
Promis Neurosciences N/A -933.63%-295.33%

Promis Neurosciences has lower revenue, but higher earnings than Gossamer Bio. Promis Neurosciences is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer Bio$48.47M1.63-$170.37M-$0.75N/A
Promis NeurosciencesN/AN/A-$39.72M-$19.00N/A

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 7.2% of Gossamer Bio shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Gossamer Bio had 23 more articles in the media than Promis Neurosciences. MarketBeat recorded 25 mentions for Gossamer Bio and 2 mentions for Promis Neurosciences. Gossamer Bio's average media sentiment score of 0.11 beat Promis Neurosciences' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gossamer Bio
0 Very Positive mention(s)
0 Positive mention(s)
25 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Promis Neurosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Gossamer Bio has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.2, suggesting that its share price is 120% less volatile than the S&P 500.

Gossamer Bio presently has a consensus target price of $5.43, indicating a potential upside of 1,515.65%. Promis Neurosciences has a consensus target price of $42.67, indicating a potential upside of 285.77%. Given Gossamer Bio's higher probable upside, equities research analysts clearly believe Gossamer Bio is more favorable than Promis Neurosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Gossamer Bio beats Promis Neurosciences on 12 of the 15 factors compared between the two stocks.

How does Promis Neurosciences compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

eXoZymes' return on equity of -147.18% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
eXoZymesN/A -147.18% -104.98%
Promis Neurosciences N/A -933.63%-295.33%

eXoZymes is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eXoZymesN/AN/A-$9.16M-$1.08N/A
Promis NeurosciencesN/AN/A-$39.72M-$19.00N/A

50.1% of Promis Neurosciences shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Promis Neurosciences had 2 more articles in the media than eXoZymes. MarketBeat recorded 2 mentions for Promis Neurosciences and 0 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.00 equaled Promis Neurosciences'average media sentiment score.

Company Overall Sentiment
eXoZymes Neutral
Promis Neurosciences Neutral

eXoZymes has a beta of 2.85, suggesting that its share price is 185% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.2, suggesting that its share price is 120% less volatile than the S&P 500.

Promis Neurosciences has a consensus target price of $42.67, indicating a potential upside of 285.77%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Promis Neurosciences is more favorable than eXoZymes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
eXoZymes
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

eXoZymes and Promis Neurosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Promis Neurosciences compare to biote?

biote (NASDAQ:BTMD) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

21.7% of biote shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 32.4% of biote shares are owned by insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

biote has higher revenue and earnings than Promis Neurosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
biote$192.22M0.45$27.05M$0.752.95
Promis NeurosciencesN/AN/A-$39.72M-$19.00N/A

In the previous week, biote had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for biote and 2 mentions for Promis Neurosciences. biote's average media sentiment score of 0.00 equaled Promis Neurosciences'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
biote
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Promis Neurosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

biote has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.2, suggesting that its stock price is 120% less volatile than the S&P 500.

biote has a net margin of 14.07% compared to Promis Neurosciences' net margin of 0.00%. biote's return on equity of -23.41% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
biote14.07% -23.41% 14.63%
Promis Neurosciences N/A -933.63%-295.33%

biote currently has a consensus price target of $2.75, indicating a potential upside of 24.43%. Promis Neurosciences has a consensus price target of $42.67, indicating a potential upside of 285.77%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Promis Neurosciences is more favorable than biote.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
biote
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

biote beats Promis Neurosciences on 10 of the 14 factors compared between the two stocks.

Get Promis Neurosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PMN vs. The Competition

Export
MetricPromis NeurosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$99.21M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-0.5838.8529.0428.47
Price / SalesN/A155.51476.6160.92
Price / CashN/A57.8827.6236.52
Price / Book-19.077.039.676.67
Net Income-$39.72M$23.62M$3.55B$332.53M
7 Day Performance1.94%3.68%1.70%2.01%
1 Month Performance-11.59%7.16%5.62%9.19%
1 Year Performance-30.88%67.05%34.41%39.59%

Promis Neurosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PMN
Promis Neurosciences
2.8827 of 5 stars		$11.06
-0.1%		$42.67
+285.8%		N/A$99.21MN/AN/A5
COEP
Coeptis Therapeutics
N/A$15.10
+1.1%		N/AN/A$93.97M$1.36MN/A2
FRMM
Forum Markets
0.2567 of 5 stars		$4.60
+13.9%		$5.00
+8.7%		N/A$93.43M$6.55MN/A7
GOSS
Gossamer Bio
2.5134 of 5 stars		$0.39
+3.3%		$5.43
+1,292.3%		N/A$91.51M$48.47MN/A180
EXOZ
eXoZymes
0.2395 of 5 stars		$10.46
-0.2%		N/AN/A$88.66M$70KN/A29

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PMN) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel